It blocks metastasis by inhibiting the adhesion of cancer cells to the extracellular matrix (ECM) of proteins such as collagen, fibronectin, laminin and blocking 90–95% of all stages of the platelet aggregation process and 95% of the angiogenesis process [18,21] Mass production of GIP would allow the spectrum of cancer drugs, for treatment both estrogen-dependent and independent cancers, to be expanded. Here, FN1 is linked to cancer.